Emerging Microbes and Infections (Jan 2020)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection

  • Romina Salpini,
  • Arianna Battisti,
  • Lorenzo Piermatteo,
  • Luca Carioti,
  • Olympia E. Anastasiou,
  • Upkar S. Gill,
  • Domenico Di Carlo,
  • Luna Colagrossi,
  • Leonardo Duca,
  • Ada Bertoli,
  • Katia Yu La Rosa,
  • Lavinia Fabeni,
  • Alessandra Iuvara,
  • Vincenzo Malagnino,
  • Carlotta Cerva,
  • Miriam Lichtner,
  • Claudio M. Mastroianni,
  • Giuseppe Maria De Sanctis,
  • Maurizio Paoloni,
  • Massimo Marignani,
  • Caterina Pasquazzi,
  • Nerio Iapadre,
  • Giustino Parruti,
  • Jacopo Vecchiet,
  • Loredana Sarmati,
  • Massimo Andreoni,
  • Mario Angelico,
  • Sandro Grelli,
  • Patrick T. Kennedy,
  • Jens Verheyen,
  • Stefano Aquaro,
  • Francesca Ceccherini-Silberstein,
  • Carlo Federico Perno,
  • Valentina Svicher

DOI
https://doi.org/10.1080/22221751.2020.1757998
Journal volume & issue
Vol. 9, no. 1
pp. 928 – 939

Abstract

Read online

ABSTRACTIncreasing evidences suggest that HBsAg-production varies across HBV-genotypes. HBsAg C-terminus plays a crucial role for HBsAg-secretion. Here, we evaluate HBsAg-levels in different HBV-genotypes in HBeAg-negative chronic infection, the correlation of specific mutations in HBsAg C-terminus with HBsAg-levels in-vivo, their impact on HBsAg-secretion in-vitro and on structural stability in-silico.HBsAg-levels were investigated in 323 drug-naïve HBeAg-negative patients chronically infected with HBV genotype-D(N = 228), -A(N = 65) and -E(N = 30). Genotype-D was characterized by HBsAg-levels lower than genotype-A and -E (3.3[2.7–3.8]IU/ml; 3.8[3.5–4.2]IU/ml and 3.9[3.7–4.2]IU/ml, P < 0.001). Results confirmed by multivariable analysis correcting for patients’demographics, HBV-DNA, ALT and infection-status.In genotype-D, specific C-terminus mutations (V190A-S204N-Y206C-Y206F-S210N) significantly correlate with HBsAg<1000IU/ml(P-value from <0.001 to 0.04). These mutations lie in divergent pathways involving other HBsAg C-terminus mutations: V190A + F220L (Phi = 0.41, P = 0.003), S204N + L205P (Phi = 0.36, P = 0.005), Y206F + S210R (Phi = 0.47, P < 0.001) and S210N + F220L (Phi = 0.40, P = 0.006). Notably, patients with these mutational pairs present HBsAg-levels 1log lower than patients without them(P-value from 0.003 to 0.02). In-vitro, the above-mentioned mutational pairs determined a significant decrease in HBsAg secretion-efficiency compared to wt(P-value from <0.001 to 0.02). Structurally, these mutational pairs reduced HBsAg C-terminus stability and determined a rearrangement of this domain.In conclusion, HBsAg-levels in genotype-D are significantly lower than in genotype-A and -E in HBeAg-negative patients. In genotype-D, specific mutational clusters in HBsAg C-terminus correlate with lower HBsAg-levels in-vivo, hamper HBsAg-release in-vitro and affect its structural stability, supporting their detrimental role on HBsAg-secretion. In this light, genotypic-testing can be a valuable tool to optimize the clinical interpretation of HBsAg in genotype-D and to provide information on HBV-pathogenicity and disease-progression.

Keywords